This One Factor Will Determine if Pfizer Can Dominate the Kids' Vaccine Market
Pfizer (NYSE: PFE) just scored another first. The company became the first to submit data to the U.S. Food and Drug Administration (FDA) that would support an authorization of its coronavirus vaccine in children under age 12. Pfizer was the first to market a coronavirus vaccine -- and the first to gain authorization for use in teens.
Pfizer plans to submit a formal request for the kids' market in the next few weeks. If the FDA gives Pfizer the nod, the company may not be alone in the market for long. Close rival Moderna also is investigating its vaccine in kids and probably will submit data to the FDA soon.
So, what does Pfizer have to do to become the leader in this market? It isn't a matter of just reaching commercialization first. In fact, there is one element that likely will determine whether Pfizer will dominate the kids' vaccine market. And this element is beyond Pfizer's control. Let's take a closer look.
Source Fool.com
